Masahiro Shinada

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Induced Pluripotent Stem Cells

Top Venues

Scientific reports

Molecular cancer research : MCR

Veterinary and comparative oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shotaro Eto, Daiki Kato, Kohei Saeki, Takaaki Iguchi, Qin Shiyu, Satoshi Kamoto, Ryohei Yoshitake, Masahiro Shinada, Namiko Ikeda, Masaya Tsuboi, James Chambers, Kazuyuki Uchida, Ryohei Nishimura, Takayuki Nakagawa
Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade. Veterinary and comparative oncology (2024)
Masahiro Shinada, Daiki Kato, Tomoki Motegi, Masaya Tsuboi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Toshio Li, Yuka Kodera, Ryosuke Ota, Yuko Hashimoto, Yosuke Takahashi, James K Chambers, Kazuyuki Uchida, Yukinari Kato, Ryohei Nishimura, Takayuki Nakagawa
Podoplanin drives amoeboid invasion in canine and human mucosal melanoma. Molecular cancer research : MCR (2023)
Ryohei Yoshitake, Kohei Saeki, Shotaro Eto, Masahiro Shinada, Rei Nakano, Hiroshi Sugiya, Yoshifumi Endo, Naoki Fujita, Ryohei Nishimura, Takayuki Nakagawa
Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. Scientific reports 10 (1) (2020)
Ryohei Yoshitake, Kohei Saeki, Shotaro Eto, Masahiro Shinada, Rei Nakano, Hiroshi Sugiya, Yoshifumi Endo, Naoki Fujita, Ryohei Nishimura, Takayuki Nakagawa
Author Correction: Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. Scientific reports 10 (1) (2020)
Satoshi Kamoto, Masahiro Shinada, Daiki Kato, Sho Yoshimoto, Namiko Ikeda, Masaya Tsuboi, Ryohei Yoshitake, Shotaro Eto, Yuko Hashimoto, Yosuke Takahashi, James Chambers, Kazuyuki Uchida, Mika K Kaneko, Naoki Fujita, Ryohei Nishimura, Yukinari Kato, Takayuki Nakagawa
Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells 9 (11) (2020)